Pulmonary fibrosis is a progressive lung disease characterized by myofibroblast accumulation and 24 excessive extracellular matrix deposition. Endoplasmic reticulum (ER) stress initiates the unfolded 25 protein response (UPR), a cellular stress response pathway that has been implicated in both 26 inflammatory and fibrotic processes. Here, we sought to investigate the role of the 13 kDa FK506-27 binding protein (FKBP13), an ER stress-inducible molecular chaperone, in various forms of pulmonary 28 fibrosis. We first characterized the gene and protein expression of FKBP13 in lung biopsy samples 29 from 24 patients with idiopathic pulmonary fibrosis (IPF) and 17 control subjects. FKBP13 expression 30 was found to be elevated in the fibrotic regions of IPF lung tissues, and within this cohort, was 31 correlated with declining forced vital capacity and dyspnea severity. FKBP13 expression was also 32 increased in lung biopsies of patients with hypersensitivity pneumonitis, rheumatoid arthritis, and 33 sarcoidosis-associated interstitial lung disease. We next evaluated the role of this protein using 34 FKBP13 -/mice in a bleomycin model of pulmonary fibrosis. Animals were assessed for lung function 35 and histopathology at different stages of lung injury including the inflammatory (Day 7), fibrotic (Day 36 21) and resolution (Day 50) phase. FKBP13 -/mice showed increased infiltration of inflammatory cells 37 and cytokines at Day 7, increased lung elastance and fibrosis at Day 21, and impaired resolution of 38 fibrosis at Day 50. These changes were associated with an increased number of cells that stained 39 positive for TUNEL and cleaved caspase 3 in the FKBP13 -/lungs, indicating a heightened cellular 40 sensitivity to bleomycin. Our findings suggest that FKBP13 is a potential biomarker for severity or 41 progression of interstitial lung diseases, and that it has a biologically relevant role in protecting mice 42 against bleomycin-induced injury, inflammation and fibrosis. 43 following the description provided by Reyfman et al. (2018) [19] using Seurat [20] package in R. t-131 distributed stochastic neighbor embedding (tSNE plot), expression plot and violin plots were created 132 using Seurat package. Cell populations were defined by using the genes reported to be differentially 133 expressed between the cell populations [19]. 134 Animal Experiments: All animal work was approved by the Animal Research Ethics Board of 135 McMaster University (Hamilton, ON, Canada) under protocol number 12.02.06. Male C57BL6/J mice 136 aged 10-12 weeks were bred and housed at the McMaster University Central Animal Facility (CAF, 137
INTRODUCTION 44
Pulmonary fibrosis results in the progressive scarring and stiffening of the lungs, eventually 45 leading to respiratory failure [1] . Most cases are diagnosed as idiopathic pulmonary fibrosis (IPF), but 46 secondary causes such as genetic susceptibility, environmental pollutants, medications and radiation 47 exposure have been identified. Although a complete understanding of the cellular mechanisms involved 48 in the pathogenesis of fibrotic lung disease remains elusive, accumulating evidence demonstrates that 49 injury to the lung epithelium stimulates the accumulation of myofibroblasts which are responsible for 50 the excessive deposition of extracellular matrix (ECM) components into the interstitium, causing 51 decreased lung compliance and impaired gas exchange [1] . 52
The endoplasmic reticulum (ER) is the site of protein biosynthesis and folding. Disruption of 53 homeostasis in this organelle causes ER stress and activation of the unfolded protein response (UPR), 54 which have been shown to contribute to the development of various fibrotic disorders including IPF [2, 55 3]. Activation of the UPR pathway in mammalian cells is thought to be triggered by the dissociation of 56 Glucose-Regulated Protein 78 (GRP78) from three ER transmembrane proteins: inositol-requiring 57 enzyme 1 (IRE1), activating transcription factor 6 (ATF6), and protein kinase RNA-like endoplasmic 58 reticulum kinase (PERK). Activation of these pathways results in the upregulation of transcription 59 factors and chaperones that increase the protein folding capacity of the ER and promote the degradation 60 of misfolded or unfolded proteins [4] . Failure to restore ER homeostasis can lead to the initiation of 61 apoptotic pathways through the transcription factor C/EBP-homologous protein (CHOP). 62 A distinct family of immunophilins termed the FK506-binding proteins (FKBPs) has been 63 noted to play an important role in both connective tissue remodeling and the ER stress response [5, 6] . 64
The mechanism by which FKBPs facilitate remodeling is thought to occur through their peptidyl-65 prolyl cis/trans-isomerase (PPIase) activity, which alters the peptidyl-prolyl bonds in proteins. 66 FKBP65 is one such member of the family that is upregulated in lung tissue of IPF patients and that is 67 necessary for collagen production by lung fibroblasts [5] . FKBP65 associates with GRP78 and the 68 collagen-specific chaperone HSP47 during collagen assembly and its deficiency in mouse embryos 69 results in altered collagen trafficking and aggregation of procollagen within the ER [7-9]. Here, we 70 characterize the role of another one of the 15 members of FKBP family, the 13-kDa FK506-binding 71 protein (FKBP13), in IPF patients and an experimental mouse model of bleomycin-induced lung 72 fibrosis. 73 FKBP13 is localized to the lumen of the ER and is induced during ER stress [10] [11] [12] . It also 74 shares 50% homology with other UPR chaperones GRP78 and GRP94, suggesting that FKBP13 itself 75 also functions as a chaperone [11] . Boon et al. (2009) observed that FKBP13 gene expression was 76 upregulated 5-fold in the lung tissue of patients with progressive IPF compared to those with stable 77 disease [13] . Similar observations have been made in a cohort of patients with progressive 78 hypersensitivity pneumonitis [14] . Unlike FKBP65, FKBP13 has lower activity towards post-79 translationally modified procollagen and does not appear to play a role in collagen folding [15] . 80
Recently, it was shown that FKBP13 protects plasma cells from ER stress-induced apoptosis by 81 promoting the degradation of misfolded immunoglobulins [16] . We postulated that the upregulation of 82 FKBP13 in fibrotic lung tissue acts to protect cells against ER stress. However, as shown in our 83 previous studies, its overall effect on the development of fibrosis depends on the specific cell types that 84 are affected [17] . 85
To further investigate the roles of FKBP13 in the pathogenesis of pulmonary fibrosis, we began 86 by constructing a tissue microarray comprised of lung biopsies from IPF and control patients. This was 87 used to investigate the expression pattern of FKBP13 at the protein and mRNA levels and to assess the 88 association between FKBP13 expression and lung function in the patients. We then generated FKBP13-89 knockout (FKBP13 -/-) mice and subjected them to a model of bleomycin-induced pulmonary fibrosis. 90
In these experiments, we observed that FKBP13 -/mice are more susceptible to injury by bleomycin, 91 resulting in more severe pulmonary fibrosis at lower doses of the drug. These data suggest that 92 FKBP13 plays a protective role in the pathogenesis of pulmonary fibrosis. 93
Materials and Methods 94
Human Lung Resected Tissue: All procedures using human tissues were approved by the Hamilton 95 Integrated Research Ethics Board (11-3559 and 13-523-C). Formalin-fixed paraffin-embedded (FFPE) 96 human lung tissue were obtained from the biobank for lung diseases at St. Joseph's Hospital in 97
Hamilton Ontario. IPF (n=30), hypersensitivity pneumonitis (n=5), rheumatoid arthritis (n=6) and 98 sarcoidosis (n=6) cases were selected based on clinical history, radiographic appearance and a pattern 99 of usual interstitial pneumonia or fibrotic granulomas as determined by trained molecular pathologists 100 and radiologists. Non-involved tissue from lung cancer cases (n=17) was used as controls. Upon 101 confirmation of a positive diagnosis, patient slides were scanned using the Olympus VS120 Slide 102 Scanner and 0.6 mm diameter fibrotic and non-fibrotic cores were selected to be placed into a tissue 103 microarray (TMA) block. Fibrotic regions were identified based on features of UIP including spatial 104 heterogeneity in the parenchyma, architectural distortion and fibroblastic foci. In total, 316 cores were 105 selected with at least 3 cores for each specified area. Generation of FKBP13-Deficient Mice by Gene Targeting: FKBP13-deficient animals were initially 141 generated in 129SvEvBrd embryonic stem cells (Taconic Biosciences, NY), and chimeric mice were 142 made on a C57BL/6J (Jackson laboratory) background to produce F2 homozygous mutants by Dr. 143
Barbara Hendrickson (University of Chicago). Jackson Laboratory re-derived these mice in the 144 C57BL/6J strain and they were further back-crossed for 7 generations onto a C57BL6/J background. 145
Mice heterozygous (FKBP13 +/-) and homozygous (FKBP13 -/-) for the FKBP13 mutation were 146 characterized by Southern blot analyses of tail genomic DNA. Northern blot analyses of RNA from 147 WT (FKBP13 +/+ ) brain, kidney, liver, and spleen revealed easily detectable 0.6 kB FKBP13 mRNA. 148
However, no FKBP13 mRNA was detected in FKBP13 -/mouse-derived tissues despite loading similar 149 amounts of RNA for all samples, as judged by actin probe hybridization. Immunostaining for FKBP13 150 using an anti-FKBP13 antiserum (a gift from Dr. S. Burakoff, Dana-Faber Cancer Institute, Boston, 151 MA) confirmed a lack of FKBP13 protein in the FKBP13 -/lung tissue ( Figure 3A) . 152
Bleomycin administration and collection of samples: Experimental pulmonary fibrosis was induced 153
by intratracheal intubation of bleomycin (Hospira, NDC 61703-332-18) in isoflurane-anesthetized 154 mice (MTC Pharmaceuticals, Canada) at 0.04 or 0.06U per mouse. Bleomycin was solubilized in 50µl 155 sterile saline. Lung tissues and BALF were isolated and processed as described previously [17] . BALF 156 differential cell counts were then performed by counting 300 leukocytes and using hemocytological 157 procedures to classify the cells as neutrophils, macrophages, eosinophils or lymphocytes and 158 multiplying the relative abundance of each cell type by the BALF total cell count. Mouse lung tissues 159 were fixed and embedded in paraffin, and a TMA containing 135 cores of 1.5 mm diameter was 160 generated using the TMA Master platform (3DHISTECH, Hungary). Three cores were obtained from 161 each mouse lung, providing complete coverage of the lung area. Histological staining was performed 162 on this TMA as described above. Semi-quantitative histological analysis of pulmonary fibrosis was 163 performed through Ashcroft scoring as described previously [17] . 164
Immunofluorescence: Immunofluorescence staining of FKBP13 (R&D systems, Minneapolis, MN, 165 MAB4356) and E-cadherin (Abcam, ab1416). Following deparaffinization and saturation of 166 nonspecific sites with BSA (5%, 30 min), cells were incubated with primary antibodies overnight in a 167 humidified chamber at 4°C. Conjugated secondary antibodies were used at a dilution of 1:2000. Slides 168
were mounted in Prolong-gold with DAPI (ProLong® Gold antifade regent with DAPI, Life 169 technologies, P36931). Images were taken using an epifluorescence microscope (Olympus IX81, 170
Olympus, ON, Canada) and analyzed with MetaMorph® Image Analysis Software (Molecular 171 Devices). 172
Assessment of pulmonary mechanics: Lung function measurements, including pressure-volume loops 173
and Quasi-static elastance were performed as described previously [17] . 174
Statistical analysis: Results were expressed as mean ± SEM. Two groups were compared with a two-175 tailed unpaired Student's t-test. When more than two groups were compared, a one-way ANOVA 176 followed by Newman-Keuls multiple comparison test was used. Statistical tests were employed using 177 GraphPad Prism 7 (GraphPad Software, Inc). A p-value of <0.05 was considered statistically 178 significant. 179
180

RESULTS
181
FKBP13 expression is increased in the fibrotic regions of IPF patients and is correlated with 182
clinical severity. 183 FKBP13 was previously shown to be upregulated at the mRNA level in patients with 184 progressive IPF and other interstitial lung diseases [13] . Here, we aimed to characterize the expression 185 of FKBP13 by immunohistochemistry (IHC) in the lungs of IPF patients. A tissue microarray was 186 designed containing fibrotic and non-fibrotic cores taken from lung biopsies of 24 IPF patients and 17 187 control subjects. Demographic information and clinical characteristics of these patients are presented in 188 Table 1 . FKBP13 levels were higher in the fibrotic regions of IPF tissues compared to non-fibrotic 189 regions and healthy control tissues (Figure 1A,B) . Total RNA isolated from FFPE tissues was assessed 190 for FKBP13 using Nanostring gene expression analysis. Consistent with the IHC findings, FKBP13 191 mRNA levels were elevated in the fibrotic tissues ( Figure 1C) . To determine the specific cellular 192 subpopulations that express FKBP13, the open-access single-cell RNAseq dataset by Reyfman et al. 193 (2018) was analyzed. Cells were clustered using tSNE and clusters were assigned to cell populations 194 based on the genes reported as markers (Figure S1A,B) . With the pooled data from lung biopsies of 4 195 IPF patients and 8 controls, FKBP13 was found to be ubiquitously expressed by all cellular 196 subpopulations in the lung (Figure S1C ) [19] . FKBP13 was noted to be significantly upregulated in the 197 IPF plasma cell population. 198
Within the cohort of IPF patients, the expression of FKBP13 in the fibrotic cores was correlated 199 with clinical parameters of disease severity. Specifically, we found a negative correlation with forced 200 vital capacity (FVC) and a positive correlation with patient-reported dyspnea scores (Figure 1D,E) . 201
We further assessed the correlation of FKBP13 with other molecular markers of fibrosis, ER stress and 202 apoptosis that have been linked to the development of IPF [21] . At the protein level, FKBP13 was 203 positively correlated with the myofibroblast marker α -smooth muscle actin (αSMA) and the UPR 204 markers GRP78 and total XBP1 (Figure 1G-I) . This was corroborated at the mRNA level, with 205 FKBP13 showing positive correlations with GRP78, total XBP1, CHOP and Bax, and a negative 206 correlation with Bim (Figure 1K-M) . In summary, higher levels of FKBP13 in fibrotic IPF tissues are 207 associated with increased clinical severity and activation of UPR and apoptosis pathways, which may 208 contribute to the disease pathogenesis. 209
We hypothesized that FKBP13 would also be upregulated in other forms of fibrotic lung 210 disease. A second tissue microarray was constructed to assess the expression of FKBP13 in 211 hypersensitivity pneumonitis, rheumatoid arthritis, and sarcoidosis-associated interstitial lung disease, 212 in addition to an independent cohort of IPF patients. Baseline demographic and clinical data are shown 213
in Table 2 . Histopathological analysis of the FKBP13 staining by a molecular pathologist showed that 214 FKBP13 appears primarily localized in the bronchial and alveolar epithelium, and in alveolar 215 macrophages (Figure 2A) . FKBP13 expression was found to be significantly elevated in the fibrotic 216 regions of these tissues compared to control tissues (Figure 2B) . These findings provide further 217 support to potential role of FKBP13 in interstitial lung diseases. 218 219 FKBP13 expression is increased in the lung tissue of bleomycin-treated mice. 220
Because of the upregulation of FKBP13 in various fibrotic lung diseases and its association 221 with declining lung function and ER stress, we further explored the role of this protein in the 222 development of pulmonary fibrosis by generating FKBP13 knockout (FKBP13 -/-) mice. We induced 223 pulmonary fibrosis using a single intratracheal 0.06U dose of bleomycin, and FKBP13 levels were 224 assessed by IHC. In wildtype (WT) mice, FKBP13 was significantly upregulated at Day 7 and Day 21 225 post-bleomycin administration (Figure 3A,B) . Based on histopathological analysis by a molecular 226 pathologist, it was noted that FKBP13 was primarily localized in bronchial and alveolar epithelial cells, 227 similar to the IPF tissues ( Figure 3A) . There was no FKBP13 staining present in FKBP13 -/mice, 228 providing validation for the knockout. Dual immunofluorescence analysis of WT lung tissues further 229 confirmed the colocalization of FKBP13 with the epithelial cell marker E-cadherin (Figure 3C) . Of 230 note, the colocalization of FKBP13 and E-cadherin peaked at Day 7 (90.8±2.1%) before returning to 231 baseline at Day 21 (Figure 3D) . 232
FKBP13 knockout increases susceptibility to bleomycin-induced pulmonary fibrosis. 233
To determine if FKBP13 -/mice developed a different fibrotic response to bleomycin 234 administration compared to control mice, two doses of bleomycin, 0.04U or 0.06U/mouse, were 235 delivered intratracheally to WT and FKBP13 -/mice. Mice were then assessed for changes in lung 236 function at Day 21 using a mechanical ventilator (Flexivent). At the lower dose of bleomycin (0.04U), 237
WT mice were unaffected with respect to lung function and histopathology, while FKBP13 -/mice 238 displayed increased static lung elastance (Figure 4A; Figure S2A) . At the higher dose of bleomycin 239 (0.06U), both WT and FKPB13 -/mice experienced a similar elevation in lung elastance at Day 21 240 ( Figure 4B; Figure S2B) . 241
To determine whether the higher elastance measurement of the FKBP13 -/lungs at Day 21 242 correlated with an increase in fibrogenesis, histopathological analysis of the lung tissues was 243 performed. Consistent with the lung stiffness measurements, the lower dose of bleomycin led to 244 increased collagen deposition in the lung parenchyma of the FKBP13 -/mice, while WT mice were 245 unaffected (Figure 4C,D) . The fibrotic lung parenchyma of FKBP13 -/mice also showed increased 246 α SMA immunostaining compared to WT mice, indicating an accumulation of myofibroblasts ( Figures  247   4E,F) . At the higher bleomycin dose, the extent of fibrosis and myofibroblast accumulation was 248 relatively similar in both strains at Day 21. Taken together, these results show that FKBP13 -/mice are 249 more susceptible to bleomycin-induced lung injury, suggesting that FKBP13 is involved in processes 250 that protect against either injury or fibrogenesis. 251 252 13 253
FKBP13 deficiency increases lung inflammation after bleomycin administration. 254
To determine whether the exaggerated fibrotic processes in the FKBP13 -/mice are due in part 255 to their susceptibility towards bleomycin-induced pulmonary inflammation, we assessed the 256 inflammatory profile of the BALF collected from the mice, which included total cell infiltrates, cell 257 differentials, TGF-β1 and IL-6 levels. This was done both at the peak of the inflammatory phase (Day 258 7) and the fibrotic phase (Day 21) after bleomycin instillation. At Day 7, the lower dose of bleomycin 259 (0.04U) led to an influx of inflammatory cells in both WT and FKBP13 -/mice compared to their 260 respective controls; however, the FKBP13 -/mice showed a two-fold greater influx over the WT mice 261 ( Figure 5A) . FKBP13 -/mice had increased infiltration of macrophages, neutrophils and lymphocytes 262 at Day 7 compared to WT mice (Figure 5B-D) . There were no differences in the amount and 263 phenotype of inflammatory cells at Day 21 post-bleomycin administration. Levels of the pro-264 inflammatory cytokine IL-6 were elevated in both strains at Day 7, but to a 2-fold greater extent in 265 FKBP13 -/compared to WT lungs (Figure 5E) . Levels of the pro-fibrotic cytokine TGF-β1 were also 266 higher in FKBP13 -/mice compared to WT mice at Day 7 (Figure 5F) . At Day 21, the level of TGF-β1 267 was below detection. This data demonstrates that although both strains experience a pro-inflammatory 268 response at Day 7, the response is intensified in the FKBP13 -/mice. 269 FKBP13 -/mice demonstrated a significant increase in the number of TUNEL-positive cells (Figure  274   6A,B) . Higher numbers of apoptotic cells were also seen in the knockout lung tissues at Day 21 by 275 cleaved caspase 3 immunostaining (Figure 6C,D) . Histopathological analysis suggested that type II 276 alveolar epithelial cells were the predominant cell type affected. 277
Resolution of bleomycin-induced pulmonary fibrosis is impaired in FKBP13 -/mice 278
A characteristic of the bleomycin model is the reversibility of the fibrosis in the afflicted 279 animals [22] . To determine if FKBP13 deficiency affects this process, lung stiffness and fibrosis 280 measurements were made at 50 days following the administration of high dose (0.06U) bleomycin. As 281 reported earlier, this dose causes both strains develop a similar severity of fibrosis at Day 21 ( Figure  282   4) . At Day 50, lung stiffness in the WT mice returned to baseline, while remaining elevated in the 283 FKBP13 -/mice (Figure 7A,B) . Fibrotic tissue area also persisted in the FKBP13 -/mice while 284 normalizing in the WT mice (Figure 7C,D In this study, we investigated the role of the ER resident molecular chaperone, FKBP13, in 291 patients diagnosed with IPF and in an in vivo system which models the pathogenesis of pulmonary 292 fibrosis. Previously, FKBP13 has been identified as a gene that is upregulated in the lung tissue of 293 patients with progressive IPF, as defined by a ≥ 10% decline in FVC and ≥ 15% decline in DL CO over 294 the 12 months following the biopsy [13] . Furthermore, FKBP13 expression was found to be elevated in 295 a cohort of patients with rapidly progressive chronic hypersensitivity pneumonitis, a disease that is also 296 characterized by inflammation and progressive fibrosis [14] . In our present study, we corroborate these 297 findings at the protein level, with higher expression of FKBP13 detected in the fibrotic lung tissue of 298 IPF, hypersensitivity pneumonitis, rheumatoid arthritis and sarcoidosis patients compared to non-299 fibrotic regions and control tissues. We also report that FKBP13 expression in IPF fibrotic lung tissue 300 correlates with parameters of disease severity such as FVC and patient-reported dyspnea scores, 301
suggesting that it could be useful as a biomarker for disease severity and progression. Our studies in 302 transgenic mice confirmed a strong pathophysiological relevance of this molecule in all stages of lung 303 injury including the inflammatory, fibrotic and resolution phases. We demonstrate that complete 304 knockout of FKBP13 in mice results in increased susceptibility to bleomycin-induced pulmonary 305 fibrosis and impaired resolution of fibrosis. 306
Bleomycin is known to induce overall ER stress levels in the mouse lung [17, 24, 25], but due 307 to the heterogeneous nature of this organ, an important question that remains is determining the specific 308 cellular subpopulations that experience this ER stress and their resulting contribution to fibrotic 309 remodeling. Activation of the UPR in response to ER stress initially leads to an adaptive adjustment of 310 protein folding capacity through the upregulation of ER resident molecular chaperones, attenuation of 311 protein synthesis, degradation of misfolded or unfolded proteins, and physical expansion of the ER 312 [26] . Failure of these cellular programs to restore ER homeostasis results in the induction of apoptosis 313 through transcription factors such as CHOP. As a component of the adaptive phase of the UPR, 314 molecular chaperones such as FKBP13 are important for promoting cell survival through the de novo 315 folding and assembly of proteins, refolding of misfolded proteins, and facilitation of proteolytic 316 degradation 16 . 317
Each cellular subpopulation of the lung has a potential role in either promoting or protecting 318 against the fibrotic remodeling process. Because of the pro-survival role of chaperones, the 319 contribution of a molecular chaperone to the pathogenesis of IPF therefore depends on its net effect on 320 all cell types in which it is expressed. Profibrotic chaperones include those that maintain the function of 321 matrix-and cytokine-producing cell types such as fibroblasts and macrophages. For example, 322 calreticulin, FKBP65, GRP78 and HSP47 are ER resident chaperones that maintain myofibroblast 323 function by regulating Type I collagen biosynthesis and incorporation into the ECM of fibrotic tissues 324 [5, 27, 28] . We have previously shown that GRP78 also contributes to the persistence of M2-like 325 macrophages in fibrotic lung tissue by protecting these cells from undergoing CHOP-mediated 326 apoptosis [17] . By contrast, antifibrotic chaperones include those that promote the maintenance of a 327 normal epithelium in response to pulmonary insults, and that restrict the function of profibrotic cell 328 types. For example, HSP70 has been shown to prevent epithelial cells from undergoing TGF-β1-329 induced epithelial-mesenchymal transition, and its overexpression in mice protects against bleomycin-330 induced pulmonary fibrosis [29] . We found, based on single-cell RNAseq analysis, that FKBP13 331 mRNA is present in all pulmonary cell types, and thus its loss can have varying degrees of impact on 332 fibrogenesis depending on the cell type affected. Histopathological analysis of FKBP13 staining in 333 fibrotic lung tissue revealed predominant expression of this protein in epithelial cells and alveolar 334 macrophages. Here, we report evidence that the complete loss of FKBP13 has a net fibrotic effect on 335 the development of pulmonary fibrosis. We further explored the impact of this loss on epithelial cell 336 injury and cellular infiltrates into the lung tissue, both of which have been shown to correlate with the 337 extent and severity of fibrosis in the bleomycin model [30, 31] . 338
Disturbance of the bronchial and alveolar epithelium through apoptosis has been observed in 339 human IPF lung tissue, and is considered to be an initial event in acute lung injury that leads to the 340 subsequent fibrotic response [21, 23, 32]. There is now increasing evidence that prolonged ER stress 341 can induce these apoptotic processes in alveolar epithelial cells [33] [34] [35] . In human IPF lung tissues, the 342 levels of FKBP13 in fibrotic regions correlated with various markers of ER stress and apoptosis, 343 indicating a potential involvement of this chaperone in these pathways. We observed here that a 344 deficiency in FKBP13 increased the sensitivity of mice to low doses of bleomycin-induced pulmonary 345
fibrosis, suggesting that the epithelium is more susceptible to injury. Consistent with this, we observed 346 an increase in apoptotic epithelial cells in the FKBP13 -/lung tissue at both Day 7 and Day 21 post-347 bleomycin administration. Given its role as a molecular chaperone, we postulate that FKBP13 serves to 348 protect epithelial cells from ER stress-mediated apoptosis by maintaining ER homeostasis. This is 349 consistent with the findings of Jeong et al. (2017) , who found that FKBP13 is induced by ER stress in 350 plasma cells and acts to limit the production of immunoglobulins in the ER, thereby preventing the 351 cells from undergoing CHOP-mediated apoptosis [16] . In our model, the loss of FKBP13 may impair 352 the ability of epithelial cells to adapt to ER stress, priming them for more apoptosis in response to an 353 exogenous insult such as bleomycin. This is consistent with previous studies in which a chaperone 354 deficiency resulted in constitutive activation of the UPR because of higher basal levels of ER stress 355 [17, 36] . Although our knockout experiments suggest that FKBP13 is antifibrotic, its upregulation in 356 both human and mouse fibrotic lung tissue could be a physiological response to cell injury and ER 357 stress. A defect in the chaperone function of FKBP13 or prolonged occupation of its binding site could 358 presumably lead to a similar phenotype as the FKBP13 -/mice. 359
The immune cells that infiltrate the lung tissue during bleomycin injury lead to the generation 360 of pro-inflammatory cytokines, which is followed by a switch at around Day 9 to pro-fibrotic signaling. 361
To investigate whether the exacerbated fibrotic response was in part due to an increased cellular 362 infiltration of FKBP13 -/lungs, we examined the inflammatory profile of the BALF. In response to the 363 low dose of bleomycin, both strains displayed cellular infiltration and significantly elevated IL-6 at 364 Day 7 over their respective controls, although the levels in the FKBP13 -/mice were two-fold greater 365 than the WT mice. We have previously shown that IL-6 potentiates the pro-fibrotic phenotype of M2 366 macrophages, driving the fibrosis resulting from bleomycin injury [37] . TGF-β1 levels were also 367 elevated in the knockout mice at Day 7, and is known to stimulate myofibroblast proliferation and 368 activation, as indicated by the increased α -SMA staining. In addition to the more robust cellular 369 infiltration seen in the knockout, the loss of FKBP13 may alter the intrinsic functioning of the 370 responding immune cells. Our single-cell RNAseq analysis found elevated FKBP13 expression in 371 plasma cells while histopathological analysis revealed positive staining of the protein in alveolar 372 macrophages. The elevated cytokine levels in FKBP13 -/mice may be the result of unopposed cytokine 373 production by these cells. It has been shown in plasma cells that FKBP13 acts to restrict IgA 374 production in order to maintain ER homeostasis and promote cell survival [16] , and therefore a similar 375 mechanism may be involved in regulating the output of cytokines. Furthermore, the milder but 376 significant acute inflammation seen in the WT mice suggests that these animals still experienced some 377 degree of lung injury in response to bleomycin but were able to resolve the injury without progressing 378 to the fibrotic stage. The increased resistance of epithelial cells to apoptosis and the subdued immune 379 response may both contribute to the protective effect of FKBP13 in WT mice. 380
The bleomycin model is characterized by an ability of the afflicted mice to recover and undergo 381 resolution of fibrosis. Several mechanisms of pulmonary fibrosis resolution have been proposed in the 382 literature, including the degradation of the fibrotic ECM, removal of myofibroblasts, re-383 epithelialization, and removal of inflammatory cells such as profibrotic macrophages [22] . At the 384 higher bleomycin dose of 0.06U, both WT and FKBP13 -/mice displayed a similar increase in lung 385 elastance measurements at Day 21, implying that although the FKBP13 -/mice are more sensitive to 386 bleomycin-induced pulmonary fibrosis, the extent of fibrosis approaches the same plateau as the 387 bleomycin dose increases. At Day 50, lung elastance returned to baseline in the WT but remained 388 elevated in the FKBP13 -/mice, suggesting that the loss of FKBP13 impairs the resolution of fibrosis in 389 the bleomycin model. 390 FK506 (tacrolimus) and rapamycin (sirolimus) are immunosuppressive drugs that bind to 391 members of the FKBP family, including FKBP13. Several clinical and animal studies have yielded 392 conflicting results regarding the effect of these drugs on pulmonary fibrosis. Inhibition of FKBP13 393 chaperone activity by these drugs could result in a similar phenotype as FKBP13 deficiency, with a 394 predisposition to epithelial injury and intensified inflammation [16] . Our findings provide a potential 395 explanation for the interstitial pneumonitis and focal pulmonary fibrosis that has been reported in 396 transplant patients being treated with these immunosuppressants [38, 39] . FK506 has shown both 397 beneficial and adverse effects on connective tissue disease-associated interstitial lung disease, with 398 improvements seen in myositis patients [40-42] and pulmonary injury reported in patients with 399 rheumatoid arthritis [43, 44] . The effect of rapamycin on bleomycin-induced pulmonary fibrosis is also 400 inconclusive, with some studies suggesting that it inhibits the development of fibrosis [45] and others 401 suggesting that it worsens the disease [46] . These studies largely attributed the effects of rapamycin to 402 its interaction with FKBP12 and the subsequent inhibition of the PI3K/AKT/mTOR pathway [45, 47] , 403 but inhibition of the other FKBPs such as FKBP13 is likely involved in its effects. The overall effect of 404 medications such as rapamycin and FK506 on pulmonary fibrosis likely depends its distribution across 405 the various cellular compartments, its relative affinity to the FKBPs, and the etiology of the disease. 406 A limitation of our study is the lack of prognostic data on the IPF patients that were enrolled. 407
Pulmonary function tests were conducted within a median of 48 days from the date of biopsy. 408
Additional data on patient survival and serial pulmonary function testing results may aid in further 409 study of the prognostic relevance of FKBP13. To further investigate the pathophysiological role of 410 FKBP13 in pulmonary fibrosis, next steps would involve the generation of tissue-specific knockouts in 411 the epithelial or myeloid lineage to stratify the effects on epithelial injury and inflammation. 412
In conclusion, our data suggests that FKBP13 is upregulated and plays a protective role in the 413 pathogenesis of pulmonary fibrosis. Mice lacking this chaperone are more susceptible to injury from 414 lower doses of bleomycin. Because FKBP13 is predominantly expressed in lung epithelial cells, we 415 postulate that the loss of FKBP13 reduces the ability these cells to respond to ER stress, priming them 416 for more injury and apoptosis in response to pulmonary insults. In human IPF lung tissues, levels of 417 FKBP13 are associated with clinical parameters of disease severity. While unlikely to be a 418 pharmacological target because of its protective role, next steps should involve validation of FKBP13 419 as a potential biomarker for the progression of fibrotic interstitial lung diseases. 420 421 TABLES 575 576 Data presented as mean±SD, unless stated otherwise. Demographic information for the lung cancer control group was unavailable. Lung biopsies from the cohort described in this table form the tissue microarray assembled for Figure 1 . 
